

## 4.0.03 DOC Cmte minutes

### Acne Guideline Committee Meeting 6

**Date:** 30th August 2019

**Location** RCOG, London

**Minutes:** Confirmed

<b>Committee members present:</b>	
Julia Cons (Chair)	Present for notes 1-6
Eugene Healy (Topic Advisor)	Present for notes 1-6
Karen Joy	Present for notes 1-6
Mohammed Rafiq	Present for notes 1-6
Jane Wilcock	Present for notes 1-6
Rebecca Penzer-Hick	Present for notes 1-6
Sarah Mackenzie	Present for notes 1-6
Colin Duncan (Co-opted GC member)	Present for notes 4 (partly)
Damian Wood	Present for notes 1-6
Ursula Philpot	Present for notes 4 (partly)
Julia Schofield	Present for notes 1-6
Jack Higgins	Present for notes 1-6

<b>In attendance:</b>		
Rachel Marshall	NGA Guideline Lead	Present for notes 1-6
Hadil Al-Etabi	NGA Project Manager	Present for notes 1-6
Stephen Murphy	NGA Clinical Adviser	Present for notes 1-6
Jinyuan Xu	NGA Clinical fellow	Present for notes 1-6
Lin Fou	NGA Senior Systematic Reviewer	Present for notes 1-6
Shalmali Deshpande	NGA Systematic Reviewer	Present for notes 1-6
Ifigeneia Mavranouzouli	NGA Senior Health Economist	Present for notes 1-6
Catrina Charlton	NICE Commissioning Manager	Present for notes 1-6

<b>Apologies:</b>
Reena Shah
Laura Kuznetsov
Stephanie Arnold
Neil Walker

**1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to 6<sup>th</sup> guideline committee meeting on the Management of acne.

The Chair informed the Committee that apologies had been received. These are noted above.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. The following interests were declared.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Jack Higgins	Lay member	Nothing to declare (new member to the committee)	N/A	Declare and participate
Julia Schofield	Consultant Dermatologist, United Lincolnshire Hospitals NHS Trust  Principal Lecturer, University of Hertfordshire	A draft vignette was considered by the UK clinical trials unit in February 2019, where I am co-applicant, to develop a bid for a trial of low dose isotretinoin. Neither a formal bid nor a formal protocol have been drafted, the trial is not registered, and no funding has been awarded. No funds from industry will be sought. If funding is awarded, my role in the trial is yet to be determined.  <b>UPDATE August</b>	Direct – non-financial professional and personal	<ul style="list-style-type: none"> <li>• Declare and participate</li> <li>• Agreed by GL and CC 23/08/2019</li> <li>• Rationale: the interest has ceased for the duration of guideline development</li> </ul>

		<p><b>2019:</b></p> <p>I will have no involvement in the work on developing a proposal for the study for low dose isotretinoin. If UK DCTU take forward development of a proposal, I will not be involved in the work around this until after January 2021 when the guideline is due to be published.</p>		
<p><b>3. Minutes of the last meeting</b></p>				
<p>The Chair asked the Committee if they wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p>				
<p><b>4. Presentations</b></p>				
<p><u>Morning presentations.</u></p> <p>The Chair introduced Rachel Marshall, NGA Guideline Lead, who gave a presentation on Making research and consensus recommendations, and reviewing draft recommendations from GC5. Rachel then followed on with another presentation on Antimicrobial prescribing guidance.</p> <p>The Committee thanked Rachel Marshall for her presentations and contribution to the development of the guideline.</p> <p>The Chair introduced Shalmali Deshpande, NGA systematic reviewer who gave a presentation on the 1.1 skin care advice review. The committee discussed this evidence and made recommendations.</p> <p>The Committee thanked Shalmali Deshpande for her presentation and contribution to the development of the guideline.</p> <p><u>Afternoon presentations.</u></p> <p>The Chair introduced Ifigeneia Mavranouzouli, NGA Senior Health Economist who gave a presentation on the utilities review.</p> <p>The Committee thanked Ifigeneia Mavranouzouli, for her presentations and contribution to the</p>				

development of the guideline.

The Chair introduced Linyun Fou, NGA Senior Systematic Reviewer who gave a presentation on Adverse effects for interventions included within the NMA.

The Committee thanked Linyun Fou for his presentation and contributions to the development of the guideline.

**5. Questions and discussion**

The Committee discussed each presentation in relation to this guideline and were given the opportunity to ask questions.

**6. Any other business**

There was no other business to discuss.

**Date of next meeting:** 11.10.2019

**Location of next meeting:** RCOG, London